TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04099615

Intervention type: PROCEDURE
Intervention: Somatosensory Evoked Potentials
Description: We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
Study: NCT01048658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Sevoflurane
Description: Subject only standard of care drug regimens for anesthesia with this procedure.
Study: NCT04055909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide low dose
Description: nangibotide 0.3 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide high dose
Description: nangibotide 1.0 mg/kg/h
Study: NCT03377712

Intervention type: DEVICE
Intervention: diaphragmatic ultrasound
Description: Evaluates the diaphragmatic mobility through images, simple and non-invasive use

Intervention type: DEVICE
Intervention: Postural evaluation
Description: Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive

Intervention type: DEVICE
Intervention: Postural evaluation
Description: Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive

Intervention type: DEVICE
Intervention: Pain evaluation
Description: by means of questionnaires

Intervention type: DEVICE
Intervention: Evaluation of the function
Description: through questionnaires

Intervention type: DEVICE
Intervention: Functional capacity assessment
Description: Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment

Intervention type: DEVICE
Intervention: Quality of life assessment
Description: through questionnaire
Study: NCT04222179

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrathın esophagogastroduodenoscope
Description: Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
Study: NCT03941210

Intervention type: OTHER
Intervention: Detection of molecular Biomarkers
Description: MicroRNA expression profile analysis by flow cytometry

Intervention type: OTHER
Intervention: Detection of molecular Biomarkers
Description: MicroRNA expression profile analysis by flow cytometry

Intervention type: OTHER
Intervention: Detection of molecular Biomarkers
Description: MicroRNA expression profile analysis by flow cytometry

Intervention type: OTHER
Intervention: Detection of molecular Biomarkers
Description: MicroRNA expression profile analysis by flow cytometry
Study: NCT01926795

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Short leg cast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short leg cast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Immobilization
Study: NCT03493906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Ambassador Support
Description: Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
Study: NCT02793752

Intervention type: OTHER
Intervention: Age
Description: Maternal Age

Intervention type: OTHER
Intervention: Age
Description: Maternal Age
Study: NCT00183209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family First
Description: Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family First
Description: Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
Study: NCT03528356

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular diet
Description: Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
Study: NCT04055909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT00933634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical cardioversion
Description: External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propafenone
Description: Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
Study: NCT02075151

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchial Thermoplasty
Description: Bronchial thermoplasty
Study: NCT04367246

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is assigned.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is assigned.
Study: NCT01019434

Intervention type: DRUG
Group type: OTHER
Intervention: temozolomide
Description: TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
Study: NCT01205568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Cutting Balloon therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Pressure Balloon Angioplasty
Study: NCT04077060

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NIPT
Description: Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: combined screening
Description: Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
Study: NCT01551771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW824575
Description: Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW824575 matched-placebo
Description: Placebo
Study: NCT00636402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Knife Tonsillectomy
Description: Cold Knife Tonsillectomy (CKT) will be done on the other side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel Sealing System Tonsillectomy
Description: Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
Study: NCT04001374

Intervention type: DRUG
Intervention: Ticagrelor
Description: 90mg tablet bid for 12 months

Intervention type: DRUG
Intervention: Ticagrelor
Description: 90mg tablet bid for 12 months

Intervention type: DRUG
Intervention: ASA
Description: enteric coated aspirin 81mg-100mg daily p.o. for 12 months
Study: NCT02383966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Carboplatin
Description: Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
Study: NCT01945866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab 0.3 mg
Description: Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal ranibizumab 0.3 mg
Description: Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Study: NCT04367246

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is assigned.
Study: NCT03374371

Intervention type: DIAGNOSTIC_TEST
Intervention: high-throughput sequencing
Description: technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations

Intervention type: DIAGNOSTIC_TEST
Intervention: high-throughput sequencing
Description: technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
Study: NCT03464019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: Etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: OTHER
Intervention: Etripamil Test Dose
Description: During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Intervention type: DRUG
Group type: OTHER
Intervention: Etripamil Test Dose
Description: During the Test Dose, etripamil administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study: NCT00117299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK222584
Description: PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
Study: NCT02638649

Intervention type: PROCEDURE
Intervention: Lung ultrasound
Description: At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.

Intervention type: DEVICE
Intervention: ultrasound
Study: NCT01626092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation with Marrow Boosting
Description: 1. Dose to total body 200 cGy in single dose~2. Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if \> 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is \>50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
Study: NCT05345275

Intervention type: OTHER
Intervention: The facial expressions analyzed
Description: The facial expressions associated with pain were analyzed by the researchers in the OpenFace program. The patient's pain scores were estimated in the Python program by combining the numerical outputs of facial expression analyses with machine learning algorithms.
Study: NCT02832635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT with avoidance of hippocampus
Description: Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT with avoidance of hippocampus
Description: Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT without avoidance of hippocampus
Description: Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT without avoidance of hippocampus
Description: Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
Study: NCT04543227

Intervention type: BEHAVIORAL
Intervention: Opioid Use 90-Days Post Treatment
Description: Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain

Intervention type: BEHAVIORAL
Intervention: Opioid Use 90-Days Post Treatment
Description: Survey conducted 90-days post treatment to determine use of opioid medications in relation to burn or knee arthroscopy pain
Study: NCT02088489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial flutter irrigated catheter
Description: A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial flutter porous tip catheter
Description: A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
Study: NCT02381015

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score: Number Format
Description: Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score: Number + Pictograph
Description: Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family History: Number Format
Description: Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family History: Number + Pictograph
Description: Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
Study: NCT00818051

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: Given as 48, 53, or 56 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Given as 48, 53, or 56 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Given as 48, 53, or 56 Gy
Study: NCT02183766

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide prebiotic
Description: 6 mL once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 6 mL once a day
Study: NCT03434158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg twice a day
Study: NCT02665572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bladder recycling
Description: Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.